Seattle Genetics (SGEN): Adcetris Could Become a Blockbuster - Needham
Get Alerts SGEN Hot Sheet
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 16
Join SI Premium – FREE
Needham & Company analyst, Chad Messer, noted that data from Seattle Genetics' (NASDAQ: SGEN) pivotal ALCANZA trial in relapsed cutaneous T-cell lymphoma (CTCL) is due in 3Q. If positive, this should add a couple thousand patients to the Adcetris label. The ECHELON trials in frontline Hodgkin's lymphoma (HL) and peripheral T-cell lymphoma (PTCL) read out is due in the 2017 to 2018 time frame. He believes positive data from these studies could make Adcetris a blockbuster.
Reviewing existing data from Adcetris and current standard of care regimens assigns a high likelihood of success to positive data from all three studies. The analyst forecasts $1.75B in 2021 North American Adcetris sales and very substantial profitability for SGEN. He views SGEN shares as undervalued even before considering its deep pipeline that includes pivotal stage vadastuximab for AML. No change to the Buy rating but the price target jumps to $72 from $60.
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $36.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rivian Automotive Inc (RIVN) PT Lowered to $13 at Needham on "slower EV adoption ahead of the R2 vehicle launch"
- Sage Therapeutics (SAGE) PT Lowered to $19 at Scotiabank
- Fuchs Petrolub SE (FPE3:GR) (FUPBY) PT Raised to EUR45 at Stifel
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, FDARelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!